GPCRs drive a huge portion of today’s drug market, but producing them in a functional form remains a major bottleneck for discovery and structural studies.
PolyActiva and RareSight are pairing pro-drug chemistry with targeted ocular delivery to address early-stage barriers in rare pediatric retinal disorders.
With multiple trials underway and billions in investment, psychedelic therapies are moving from experimental research toward mainstream mental health care.
Automation, digital manufacturing, and regulatory reform are reshaping how the UK competes in cell and gene therapy as the field moves toward routine delivery.
These late-stage therapies span obesity, diabetes, hypertension, and allergy care, offering new mechanisms and delivery formats that could reshape patient treatment.
By explicitly specifying treatment effects and intercurrent events, estimands help sponsors, clinicians, and regulators work from a shared understanding.
After decades of slow progress, advances in molecular profiling and organoid technology are creating new pathways for non-invasive diagnosis and targeted treatment of endometriosis.
Discover practical strategies to improve pipetting accuracy, reproducibility, ergonomics, and instrument performance across diverse laboratory workflows.